Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies.
Niall IgoeElliott D BayleOleg FedorovCynthia TallantPavel SavitskyCatherine RogersDafydd R OwenGauri DebTim C P SomervailleDavid M AndrewsNeil JonesAnne CheastyHamish RyderPaul E BrennanSusanne MüllerStefan KnappPaul V FishPublished in: Journal of medicinal chemistry (2017)
The BRPF (bromodomain and PHD finger-containing) family are scaffolding proteins important for the recruitment of histone acetyltransferases of the MYST family to chromatin. Evaluation of the BRPF family as a potential drug target is at an early stage although there is an emerging understanding of a role in acute myeloid leukemia (AML). We report the optimization of fragment hit 5b to 13-d as a biased, potent inhibitor of the BRD of the BRPFs with excellent selectivity over nonclass IV BRD proteins. Evaluation of 13-d in a panel of cancer cell lines showed a selective inhibition of proliferation of a subset of AML lines. Pharmacokinetic studies established that 13-d had properties compatible with oral dosing in mouse models of disease (Fpo 49%). We propose that NI-42 (13-d) is a new chemical probe for the BRPFs suitable for cellular and in vivo studies to explore the fundamental biology of these proteins.
Keyphrases
- small molecule
- early stage
- acute myeloid leukemia
- case control
- gene expression
- mouse model
- genome wide
- transcription factor
- risk assessment
- dna damage
- papillary thyroid
- oxidative stress
- quantum dots
- radiation therapy
- lymph node
- acute lymphoblastic leukemia
- young adults
- living cells
- sentinel lymph node
- locally advanced